The clinical trial focuses on patients with pancreatic cancer, colorectal cancer, and melanoma, specifically targeting those who have developed resistance to existing checkpoint therapies. By inducing DNA replication stress, pidnarulex aims to transform immune-cold tumors into environments where the immune system can effectively identify and attack cancer cells. This mechanism seeks to increase immune-cell infiltration and antigen presentation, potentially overcoming the barriers that render many current immunotherapies ineffective.

Senhwa is conducting this research in partnership with a global pharmaceutical firm, which is supplying the PD-1 inhibitor. Beyond evaluating this specific combination, the study serves as a proof-of-concept for pidnarulex as a versatile platform asset. If the trial confirms early hypotheses regarding safety and immune-sensitizing activity, the company plans to explore broader applications, including combinations with antibody-drug conjugates or radiotherapy. While the program represents a strategic expansion of Senhwa’s clinical pipeline, the company maintains that these benefits remain clinical hypotheses pending data from the upcoming patient enrollment phase.